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Introduction: Scleredema of Buschke is a rare connective tissue disorder presenting with woody
thickening and induration of the nuchal and shoulder regions resulting in progressive decrease in
the range of motion of the neck. Treatment options include several forms of systemic therapy with
variable results. Local radiation therapy (RT) is often thought of as a secondary form of therapy.
Few reports exist in the literature about the durability of its beneﬁt, however. Here, we present a
case report with the longest known follow-up after primary treatment with electron beam RT.
Methods: The patient was treated using 8-MeV en face electrons with 2000 cGy in 10 fractions with 2
separate but matched electron ﬁelds. The treatment ﬁelds included the posterior neck from the occiput
superiorly to the mid-thoracic spine inferiorly with the lateral borders extending to the scapulae. The
patient received no additional therapy either pre- or post-RT. Clinical follow-up was obtained at regular
intervals. Published literature regarding RT for this disease was reviewed and consolidated.
Results: The patient was followed at regular intervals for 6 years with signiﬁcant softening of the
plaque starting at 2 months after RT, resulting in decrease in plaque size by 50% after 18 months. The
patient regained 45 of lateral, bidirectional cervical motion from central axis and 50% improvement in
neck extension that has remained durable 6 years after treatment with no additional therapy. Quality of
life was restored with a simple nontoxic treatment limited to transient, grade 1 fatigue.
Conclusion: Scleredema of Buschke is a rare connective tissue disorder commonly treated with
multimodal therapy, but it can be effectively and durably controlled with RT alone. This case report
documents the durability of the beneﬁt achieved with RT and suggests that RT should be considered
earlier in the treatment of this disease.
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disease characterized by increased dermal thickness and
indurated erythematous plaques of the neck, a condition
that usually spreads inferiorly and symmetrically over the
shoulder region while sparing distal extremities.1-7 The
condition causes decreased range of motion, decreased
sensation, pain, and poor cosmesis, which then prompts
the workup; in rare cases, constrictive cardiopulmonary
distress is the most severe outcome.8-10 Differential con-
siderations include systemic sclerosis, scleromyxoedema
and dermatomyositis.
Three recognized types of scleredema exist: classic,
slowly progressive, and diabetic-associated, also known as
scleredema diabeticorum or scleredema adultorum. This
eponym is based on the 2.5% prevalence of indurated
plaques in poorly controlled adult diabetics.11-14 Patho-
genesis of scleredema diabeticorum involves increased
collagen glycosylation resulting in excess cross-linking,
rendering ﬁbers resistant to degradation and ultimately
increasing dermal thickness.15 Histopathology showsTable 1 Radiation therapy use in the literature for scleredema of
Author, y No. of
patients
Prior treatment Energy
Angeli-
Besson
et al.,6
1994
1 Prednisolone,
factor XIII,
cyclofenil
7-MeV
electrons
Tamburin
et al.,22
1998
1 Topical,
intralesional,
systemic
corticosteroids
Electrons
Tobler
et al.,7
2000
2 Prednisolone Mixed
12-MeV
electrons
and 6-MV
photons
Lee MW
et al.,21
2000
3 Not reported Electrons
Bowen
et al.,16
2003
3 Unspeciﬁed
systemic
treatments
Photons 6 MV
and
electrons
9-16 MeV
Konemann
et al.,9
2004
1 Penicillin,
psoralen
ultraviolet A
9-MeV
electrons
Current
paper,
2015
1 None 8-MeV
electrons
CR, complete response; fx, fraction; PR, partial response.abnormal mucin accumulation in the reticular dermis and
dermal collagen ﬁber sclerosis. In the acute setting, his-
topathologically, collagen ﬁbers are separated by hyal-
uronic acid, whereas collagen bundles are separated by
the mucopolysaccharides.2,3,10,14
Excess mucin deposition is governed by ﬁbroblast ac-
tivity, which is presumably reduced by radiation.19,20
Several mechanisms of action have been proposed,
including dermal ﬁbroblast suppression, ﬁbroblast cell
signaling interference, and apoptosis induction.6,16
Radiation-induced atrophy is not a likely mechanism
because this effect typically occurs with much higher doses
of radiation than those used for scleredema. Electrons are
typically used for cutaneous disease because they effec-
tively treat superﬁcial targets with limited or no deep tissue
penetration.
Many systemic treatments, including bath-psoralen
ultraviolet A, cyclosporine, methotrexate, extracorporeal
photopheresis, prednisolone, thyroid hormones, pituitary
extract, physiotherapy, hyaluronidase, frequency modu-
lated electromagnetic neural stimulation, and high-dose
penicillin have been usedwith variable results.4-6,12,14,17Buschke
Dose Outcome Follow-up
20 Gy/10 fx Sustained PR Not reported
20 Gy/10 fx PR 6 wk
CR at 2 y
2 y
20 Gy/10 fx PR 7 mo
24 Gy/12 fx
24 Gy/12 fx
20 Gy/10 fx
CR-PR 7 mo
5 mo
Not reported
20 Gy/10 fx
(18-21.6 Gy/
1.8-2.0 Gy)
3 initial
PR, waning
effects at 1-2 y
1 reirradiation at
1 y
2.5 years
20 Gy/10 fx,
reirradiation
with
20 Gy/10 fx
PR reirradiation
required
16 mo
20 Gy/10 fx PR in range of
motion, CR in
plaque
induration
6 y
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ment modality in several cutaneous diseases, has also been
used in refractory scleredema, although it has not been
reported as a sole treatment.18-20 Several case reports
demonstrate RT beneﬁts in medically refractory scler-
edema (Table 1). However, there is no consensus on
optimal dose. Several authors recommend 20 Gy in 10
fractions using 7 to 9 MeV electrons and they reported
excellent, sustained clinical improvement.6,22 Others have
used higher energy electrons because of the dermal rind
thickness, with minimal toxicity and marked improvement
in range of motion.
Here we present a patient successfully treated with RT
alone and followed for 6 years.Figure 1 (A, B) Treatment setup showing the top ﬁeld
covering the nuchal area and the lower ﬁeld covering the
shoulder regions. A gap was placed between the 2 ﬁelds to
minimize dose overlap.Case Report
The patient is a 72-year-old Caucasian male with
extensive cardiovascular history, obesity, and poorly
controlled diabetes mellitus. The patient’s dermatological
history includes basal cell carcinoma, seborrheic derma-
titis, rosacea, and lipodermatosclerosis. He presented to
the radiation oncology clinic for evaluation of decreased
neck extension and range of motion (ROM) 3 years after
having been diagnosed with scleredema diabeticorum. No
prior treatment was delivered because he was asymp-
tomatic and declined systemic intervention. At initial
evaluation, a very thickened plaque overlying the poste-
rior neck and upper back with limitation of neck extension
and ﬂexion of 10 to 15 and secondary shoulder kyphosis
was observed. No limitation to shoulder or arm ROM was
present. Lateral neck ROM was limited to 5 to 10 de-
grees from center. The patient sought treatment because
of a decreased quality of life from the decreased ROM of
his neck.Methods and Materials
The patient underwent computed tomography simu-
lation to measure the depth of subcutaneous tissue
involvement, w0.75 cm. At clinical simulation, he was
positioned prone on the LINAC treatment table with arms
reaching anteriorly above his head. He received 8-MeV
en face electrons dosed to the 90% isodose line to cover
the deepest extent of the lesion with 2 matched ﬁelds at
the base of the posterior neck, 1 covering the neck and
the other between the shoulders corresponding to
palpable plaque with minimal margin. Field borders were
the occiput superiorly, mid-thoracic spine inferiorly,
and to within 4 cm of his shoulder blades laterally
(Figure 1A,B). Within the ﬁelds, a 1-cm bolus was placed
on the skin to achieve full electronic equilibrium. He
received 20 Gy in 10 daily fractions based on the pub-
lished literature.Results
At the 2-month follow-up, we observed signiﬁcant
plaque softening. By 6 months, signiﬁcant decrease in
plaque size was noted but was <50%. At 18 months,
plaque size and induration decreased >50% with resolu-
tion of secondary shoulder kyphosis and stable shoulder
ROM. At 21 and 29 months, neck extension, edema, and
induration continued to improve, though with decreased
velocity. The ﬁnal follow-up at 6 years showed no evi-
dence of residual plaque (Fig 2). In summary, the lateral
ROM for his neck increased from 10 to 15 pre-RT to 45
from central axis post-RT, whereas ﬂexion/extension
improved from 10 to 15 to 20 to 30. This improvement
was most evident over the ﬁrst 3 years post-RT and was
clinically estimated (Fig 3). Over the latter 3 years, the
patient reported stabilization and perhaps subtle
improvement of the condition associated with signiﬁcant
quality of life improvement such as driving with relative
Figure 3 Improved range of motion 6 years after radiation
therapy.
Figure 2 No clinical evidence of residual plaque at 6 years’
follow-up.
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fatigue, which resolved within 1 month.
Discussion
Scleredema diabeticorum is a rare cutaneous disease
causing the formation of indurated plaques in the neck
and upper back, typically seen in adult men with poorly
controlled diabetes. Diagnosis can be challenging, and
systemic treatment options are heterogeneous. RT is
typically offered late and administered concurrently with
systemic treatments, making it difﬁcult to attribute im-
provements to RT. Brisk beneﬁts have been reported in as
little as 6 weeks; however, it is unclear if beneﬁts are due
to treatment synergy or RT.
The case presented here is unusual given a 3-year in-
terval between diagnosis and intervention as well as the
use of RT as the sole mode of treatment. Response was
durable and progressive over time. RT was also conve-
nient, brief, noninvasive, and well-tolerated. Risk of
secondary malignancy in this age group is minimal. We
therefore suggest consideration of RT for limited disease
as a primary therapy for the treatment of the adult form of
scleredema diabeticorum. Because incidence of obesity
and diabetes continues to rise, the incidence of thisdisease/condition may also rise, necessitating a greater
awareness of treatment options by clinicians.Conclusion
Scleredema diabeticorum is a benign condition char-
acterized by indurated plaques in the upper back and
neck, causing signiﬁcant morbidity and limitation in
quality of life. Treatment with multiple systemic therapies
before RT is commonplace despite the noninvasive, efﬁ-
cient, and effective nature of RT. The case presented here
conﬁrms the efﬁcacy of previously reported doses of RT
and supports its use as the only method of treatment. The
beneﬁts in increased range of motion appear to be long-
lasting, suggesting that RT should be considered as a
primary method of treatment in cases of adult scleredema
diabeticorum.References
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